ATRX and cancer: Further analysis of the patient’s tumor tissue using a targeted, capture-based next generation sequencing panel covering the full coding regions of 644 cancer associated genes showed the presence of a number of additional genetic alterations (Table 1), including an ATRX missense mutation, and amplification of MYCN, MET, and CDK4. There were no mutations in CIC or FUBP1. Other chromosomal variations, including gain of 7p and loss of 2q, 10p, 11p, 21q, and whole chromosomes 12 and 14 were also noted (Additional file 1: Table and Figure S3).